To continue getting breaking news and the full stories from The Boston Globe, subscribe today.

The Boston Globe

Business

Boston.com

In hepatitis C market, Vertex gets a big new rival

By Robert Weisman

 |  Globe Staff  

  January 10, 2012

This was supposed to be a victory lap for Vertex Pharmaceuticals Inc. executives: their first appearance at the life sciences industry’s most important annual conclave since they won long-sought approval of their potential blockbuster drug to treat hepatitis C. But the Vertex team, including its departing chief executive and his newly appointed successor, was partly upstaged by an announcement on the eve of the 30th annual J.P. Morgan Healthcare Conference that giant drug maker Bristol-Myers Squibb Co. was entering the hepatitis C market.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help

  • Phone

    888-MY-GLOBE

    Monday-Friday 6:00 a.m.- 5:00 p.m.

    Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon

  • Chat

    Start a chat

    Monday-Sunday 8:00 a.m.- 5:00 p.m.

  • E-mail

    support@bostonglobe.com